Bullous fixed drug eruption due to erlotinib: A rare case report
Fixed Drug Eruption is one of the most common cutaneous adverse drug reactions, of which the bullous variant is a more severe form. Epidermal growth factor (EGFR) inhibitors are one of the prime chemotherapeutic agents used recently in various malignancies. Most of the side effects of EGFR inhibitor...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-07-01
|
| Series: | Annals of Oncology Research and Therapy |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/aort.aort_36_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850084789567094784 |
|---|---|
| author | Kallolinee Samal Manoj Kumar Nayak Srigopal Mohanty Nibedita Dixit |
| author_facet | Kallolinee Samal Manoj Kumar Nayak Srigopal Mohanty Nibedita Dixit |
| author_sort | Kallolinee Samal |
| collection | DOAJ |
| description | Fixed Drug Eruption is one of the most common cutaneous adverse drug reactions, of which the bullous variant is a more severe form. Epidermal growth factor (EGFR) inhibitors are one of the prime chemotherapeutic agents used recently in various malignancies. Most of the side effects of EGFR inhibitors are not severe and subside by decreasing the drug dosage. There is no case report of bullous fixed drug eruption caused by EGFR inhibitors; herein, we report a rare case of bullous fixed drug eruption triggered by erlotinib, an EGFR inhibitor. |
| format | Article |
| id | doaj-art-252b7e87aa244fd0bb66e4b75721f4d5 |
| institution | DOAJ |
| issn | 2772-8382 2772-8390 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Annals of Oncology Research and Therapy |
| spelling | doaj-art-252b7e87aa244fd0bb66e4b75721f4d52025-08-20T02:43:55ZengWolters Kluwer Medknow PublicationsAnnals of Oncology Research and Therapy2772-83822772-83902025-07-015213513610.4103/aort.aort_36_24Bullous fixed drug eruption due to erlotinib: A rare case reportKallolinee SamalManoj Kumar NayakSrigopal MohantyNibedita DixitFixed Drug Eruption is one of the most common cutaneous adverse drug reactions, of which the bullous variant is a more severe form. Epidermal growth factor (EGFR) inhibitors are one of the prime chemotherapeutic agents used recently in various malignancies. Most of the side effects of EGFR inhibitors are not severe and subside by decreasing the drug dosage. There is no case report of bullous fixed drug eruption caused by EGFR inhibitors; herein, we report a rare case of bullous fixed drug eruption triggered by erlotinib, an EGFR inhibitor.https://journals.lww.com/10.4103/aort.aort_36_24bullous fixed drug eruptionerlotinibfixed drug eruption |
| spellingShingle | Kallolinee Samal Manoj Kumar Nayak Srigopal Mohanty Nibedita Dixit Bullous fixed drug eruption due to erlotinib: A rare case report Annals of Oncology Research and Therapy bullous fixed drug eruption erlotinib fixed drug eruption |
| title | Bullous fixed drug eruption due to erlotinib: A rare case report |
| title_full | Bullous fixed drug eruption due to erlotinib: A rare case report |
| title_fullStr | Bullous fixed drug eruption due to erlotinib: A rare case report |
| title_full_unstemmed | Bullous fixed drug eruption due to erlotinib: A rare case report |
| title_short | Bullous fixed drug eruption due to erlotinib: A rare case report |
| title_sort | bullous fixed drug eruption due to erlotinib a rare case report |
| topic | bullous fixed drug eruption erlotinib fixed drug eruption |
| url | https://journals.lww.com/10.4103/aort.aort_36_24 |
| work_keys_str_mv | AT kallolineesamal bullousfixeddrugeruptionduetoerlotinibararecasereport AT manojkumarnayak bullousfixeddrugeruptionduetoerlotinibararecasereport AT srigopalmohanty bullousfixeddrugeruptionduetoerlotinibararecasereport AT nibeditadixit bullousfixeddrugeruptionduetoerlotinibararecasereport |